Early animal and in vitro studies validate ImP’s direct impact on endothelial insulin signaling, NO bioavailability, and monocyte recruitment, while human cohorts consistently associate elevated ImP with higher odds of CAD, greater plaque burden, diminished left ventricular function, and increased mortality in HF. This evidence concerns the gene INS and coronary artery disorder.